コンテンツへスキップ
Merck
  • Ischemic brain extract increases SDF-1 expression in astrocytes through the CXCR2/miR-223/miR-27b pathway.

Ischemic brain extract increases SDF-1 expression in astrocytes through the CXCR2/miR-223/miR-27b pathway.

Biochimica et biophysica acta (2014-07-08)
Jin Hee Shin, Young Mi Park, Dong Hee Kim, Gyeong Joon Moon, Oh Young Bang, Takbum Ohn, Hyeon Ho Kim
要旨

Ischemic cerebral stroke is one of the leading global causes of mortality and morbidity. Ischemic preconditioning (IPC) refers to a sublethal ischemia and resulting in tolerance to subsequent severe ischemic injury. Although several pathways are reportedly involved in IPC-mediated neuroprotection, the functional role of astrocytes is not fully understood. Stromal cell-derived factor-1 (SDF-1), a CXC chemokine produced mainly in astrocytes, is a ligand for chemokine receptor CXCR4. SDF-1 is reported to play a critical role in neuroprotection after stroke by mediating the migration of neuronal progenitor cells. We hypothesized that stimuli derived from ischemic brain were involved in the protective effects of IPC. To investigate this hypothesis, the mechanism in which ischemic brain extract (IBE) induced SDF-1 expression was investigated in C6 astrocytoma cells. IBE treatment of C6 cells increased SDF-1 expression compared to that in untreated or normal brain extract (NBE)-treated cells by downregulating SDF-1 targeting miRNA, miR-27b. MiR-223 was inversely upregulated in IBE-treated cells; overexpression of miR-223 decreased the expression of miR-27b by suppressing IKKα expression. Analysis of cytokine array data revealed an IBE associated enhanced expression of CINC-1 (CXCL1) and LIX1 (CXCL5). Knockdown or inhibition of their receptor, CXCR2, abolished IBE-mediated increased expression of SDF-1. These results were confirmed in primary cultured astrocytes. Taken together, the data demonstrate that IBE-elicited signals increase SDF-1 expression through the CXCR2/miR-223/miR-27b pathway in C6 astrocytoma cells and primary astrocytes, supporting the view that increased expression of SDF-1 by ischemic insults is a possible mechanism underlying therapeutic application of IPC.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ドデシル硫酸ナトリウム, BioReagent, suitable for electrophoresis, Molecular Biology, ≥98.5% (GC)
Sigma-Aldrich
ドデシル硫酸ナトリウム, ≥99.0% (GC), dust-free pellets
Sigma-Aldrich
ドデシル硫酸ナトリウム, ACS reagent, ≥99.0%
Sigma-Aldrich
ドデシル硫酸ナトリウム 溶液, BioUltra, Molecular Biology, 10% in H2O
Sigma-Aldrich
ドデシル硫酸ナトリウム, ReagentPlus®, ≥98.5% (GC)
Sigma-Aldrich
ドデシル硫酸ナトリウム, BioUltra, Molecular Biology, ≥99.0% (GC)
Sigma-Aldrich
ドデシル硫酸ナトリウム 溶液, BioUltra, 20% in H2O
Supelco
ドデシル硫酸ナトリウム, dust-free pellets, suitable for electrophoresis, Molecular Biology, ≥99.0% (GC)
Supelco
ドデシル硫酸ナトリウム, suitable for ion pair chromatography, LiChropur, ≥99.0%
Sigma-Aldrich
ドデシル硫酸ナトリウム, BioXtra, ≥99.0% (GC)
Sigma-Aldrich
ドデシル硫酸ナトリウム, ≥98.0% (GC)
Sigma-Aldrich
ドデシル硫酸ナトリウム, 92.5-100.5% based on total alkyl sulfate content basis
Sigma-Aldrich
ドデシル硫酸ナトリウム, ≥90% ((Assay))
Sigma-Aldrich
ドデシル硫酸ナトリウム, mixture of sodium alkyl sulfates consisting mainly of sodium dodecyl sulfate
ドデシル硫酸ナトリウム, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
ドデシル硫酸ナトリウム, SAJ special grade, ≥97.0%
Sigma-Aldrich
ドデシル硫酸ナトリウム, ≥98.0% (GC)
Sigma-Aldrich
ドデシル硫酸ナトリウム, BioReagent, suitable for electrophoresis, Molecular Biology, ≥98.5% (GC), free-flowing, Redi-Dri
Sigma-Aldrich
ドデシル硫酸ナトリウム, ≥99.0%
Sigma-Aldrich
ドデシル硫酸ナトリウム, ≥99.0%
Sigma-Aldrich
ドデシル硫酸ナトリウム, SAJ first grade, ≥95.0%